Impact of delayed diagnosis time in estimating progression rates to hepatitis C virus-related cirrhosis and death

Abstract

Delay of the diagnosis of hepatitis C virus (HCV), and its treatment to avert cirrhosis, is often present sincethe early stage of HCV progression is latent. Current methods to determine the incubation time to HCV-related cirrhosis and the duration time from cirrhosis to subsequent events (e.g. complications or death) used to be based on the time of liver biopsy diagnosis and ignore this delay which led to an interval censoring for the first event time and a double censoring for the subsequent event time. To investigate the impact of this delay in estimating HCV progression rates and relevant estimating bias, we present a correlated two-stage progression model for delayed diagnosis time and fit the developed model to the previously studied hepatitis C cohort data from Edinburgh. Our analysis shows that taking the delayed diagnosis into account gives a mildly different estimate of progression rate to cirrhosis and significantly lower estimated progression rate to HCV-related death in comparison with conventional modelling. We also find that when the delay increases, the bias in estimating progression increases significantly.

Keywords

cirrhosis delayed diagnosis hepatitis C virus (HCV)progression rate two-stage model

Get full access to this article

View all access options for this article.

References

National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Gastroenterology 2002; 123(6): 2082–2099.

Salomon

Weinstein

Hammitt

Goldie

. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156: 761–773.

Hutchinson

Bird

Goldberg

. Modelling the current and future disease burden of Hepatitis C among injecting drug users in Scotland. Hepatology 2005; 42: 711–723.

Sweeting

DeAngelis

Brant

Harris

Mann

Ramsay

. The burden of hepatitis C in England. J Viral Hepat 2007; 14: 570–576.

Tom

BDM

Delahooke

Alexander

GJM

Bird

. Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol 2007; 60(11): 1140–1148.

Bonkovsky

Woolley

. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264–270.

McDonald

Hutchinson

Bird

Mills

Dillon

Bloor

. A population-based record-linkage study of mortality in hepatitis C diagnosed persons with and without HIV coinfection in Scotland. Stat Methods Med Res 2009; 18: 271–283.

McDonald

Hutchinson

Bird

Mills

Hayes

Dillon

. Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006. Epidemiol Infect 2011; 139: 344–353. doi: 10.1017/S0962280211424667.

Hutchinson

Bird

Goldberg

. Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications. Exp Rev Pharmacoeconomics Outcomes Res 2006; 6(6): 627–639.

10.

Tom

BDM

Bird

. Re-weighted inference about hepatitis C virus-infected communities when analysing diagnosed patients referred to liver clinics. Stat Methods Med Res 2009; 18: 303–320.

11.

Sweeting

De Angelis

Neal

Ramsay

Irving

Wright

. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006; 59: 144–152.

12.

Lawless

. Statistical models and methods for lifetime data, 2nd ed. New Jersey: John Wiley, 2002.

13.

Fattovich

. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21(1): 77–82.

14.

Seeff

. Natural history of chronic hepatitis C. Hepatology 2002; 36(5): Suppl. 1): 35–46.

15.

Fattovich

Giustina

Degos

. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–472.

16.

Kay

. A Markov model for analyzing cancer markers and disease states in survival studies. Biometrics 1986; 42: 855–865.

17.

Degos

Christidis

Ganne-Carrie

Farmachidi

Degott

Guettier

. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131–136.

18.

Wang

. In: Murthay

Kobbacy

AKS

(eds). Delay time modelling, in complex system maintenance handbook. Murthay P and Kobbacy AKS, Springer, 2008, pp. 345–370.

19.

Wang

Banjevic

Pecht

. A multi-component and multi-failure mode inspection model based on the delay time concept. Reliab Eng Syst Safety 2010; 95(8): 912–920.

20.

Wang

Pecht

. Economic analysis of canary-based prognostics and health management. IEEE T Ind Electronics 2010. doi: 10.1109/TIE.2010.2072897.

21.

Press

Teukolsky

Vetterling

Flannery

. Numerical recipes in C, 2nd ed. New York: Cambridge University Press, 1992.

22.

Nelder

Mead

. A simplex algorithm for function minimization. Comput J 1965; 7: 308–313.

23.

Seeff

. The history of the “natural history” of hepatitis C (1968-2009). Liver Int 2009; 29(s1): 89–99.

24.

Sweeting

Farewell

DeAngelis

. Multi-state Markov models for disease progression in the presence of informative examination times: an application to hepatitis C. Stat Med 2010; 29: 1161–1174.